Evidence map›Paper›PMID 37792826›Full record

ArticleBlood advances2023

Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A.

Takafumi Hiramoto, Hiroshi Inaba, Nemekhbayar Baatartsogt, Yuji Kashiwakura, Morisada Hayakawa, Nobuhiko Kamoshita, Hiroshi Nishimasu, Osamu Nureki, Ei Kinai, Tsukasa Ohmori

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Takafumi HiramotoDepartment of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.ORCID 0000-0003-4054-6748
Hiroshi InabaDepartment of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0003-4373-5050
Nemekhbayar BaatartsogtDepartment of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.ORCID 0000-0002-3004-8457
Yuji KashiwakuraDepartment of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.ORCID 0000-0003-0585-3937
Morisada HayakawaDepartment of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
Nobuhiko KamoshitaDepartment of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.
Hiroshi NishimasuStructural Biology Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Osamu NurekiDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-1813-7008
Ei KinaiDepartment of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0001-5415-0854
Tsukasa OhmoriDepartment of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan.ORCID 0000-0001-5082-6394
Jichi Medical University · JPThe University of Tokyo · JPTokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The importance of genetic diagnosis for patients with hemophilia has been recently demonstrated. However, the pathological variant cannot be identified in some patients. Here, we aimed to identify the pathogenic intronic variant causing hemophilia A using induced pluripotent stem cells (iPSCs) from patients and genome editing. We analyzed siblings with moderate hemophilia A and without abnormalities in the F8 exon. Next-generation sequencing of the entire F8 revealed 23 common intron variants. Variant effect predictor software indicated that the deep intronic variant at c.5220-8563A>G (intron 14) might act as a splicing acceptor. We developed iPSCs from patients and used genome editing to insert the elongation factor 1α promoter to express F8 messenger RNA (mRNA). Then, we confirmed the existence of abnormal F8 mRNA derived from aberrant splicing, resulting in a premature terminal codon as well as a significant reduction in F8 mRNA in iPSCs due to nonsense-mediated RNA decay. Gene repair by genome editing recovered whole F8 mRNA expression. Introduction of the intron variant into human B-domain-deleted F8 complementary DNA suppressed factor VIII (FVIII) activity and produced abnormal FVIII lacking the light chain in HEK293 cells. Furthermore, genome editing of the intron variant restored FVIII production. In summary, we have directly proven that the deep intronic variant in F8 results in aberrant splicing, leading to abnormal mRNA and nonsense-mediated RNA decay. Additionally, genome editing targeting the variant restored F8 mRNA and FVIII production. Our approach could be useful not only for identifying causal variants but also for verifying the therapeutic effect of personalized genome editing.

Indexed as

Hemophilia AHemostaticsInduced Pluripotent Stem CellsGene EditingHEK293 CellsHumansRNA, MessengerHemostaticsRNA, Messenger

Identifiers

PMID37792826
PMCPMC10690555
OpenAlexW4387331272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.